UNSPSC 51111875: Anastrozole

This classification denotes a non-steroidal aromatase inhibitor with the molecular formula C17H19N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2Z07MYW1AZ, chemically known as 1,3-benzenediacetonitrile, alpha,alpha,alpha,alpha-tetramethyl-5-(1h-1,2,4-triazol-1-ylmethyl)- but more generally known as anastrozole, which bears US NIH Compound Identifier 2187. European Medicines Agency schedules Anastrozole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05502MIG.

UNSPSC 51111875 Anastrozole, a Commodity code, names a specific pharmaceutical product — the aromatase inhibitor used primarily in hormone-receptor-positive breast cancer treatment — that state and local government health agencies, correctional systems, and public hospitals procure through competitive bidding and group purchasing arrangements. The code encompasses the active pharmaceutical ingredient and finished-dose formulations (typically tablets) that public health systems stock for inpatient and outpatient oncology programs, including correctional health services and safety-net hospital formularies.

The source provided contains no recent state or local contract opportunities, addenda, RFP/RFQ/IFB/ITB notices, or issuing-body activity records under this code. Without posted solicitations or awarded contract data, geographic concentration, repeat-buyer patterns, and current market activity cannot be characterized.